528 related articles for article (PubMed ID: 34208157)
21. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
Hah YS; Koo KC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
[TBL] [Abstract][Full Text] [Related]
22. Treatment Landscape of Renal Cell Carcinoma.
Chen YW; Wang L; Panian J; Dhanji S; Derweesh I; Rose B; Bagrodia A; McKay RR
Curr Treat Options Oncol; 2023 Dec; 24(12):1889-1916. PubMed ID: 38153686
[TBL] [Abstract][Full Text] [Related]
23. Liver Metastases of Unknown Primary Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors: A Case Report and Literature Review.
Bimbatti D; Cavasin N; Galuppini F; Rago A; Ramondo G; Lai E; Dionese M; Erbetta E; Basso U; Maruzzo M
Anticancer Res; 2023 May; 43(5):2359-2365. PubMed ID: 37097698
[TBL] [Abstract][Full Text] [Related]
24. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
25. [The Treatment of Metastatic Renal Cell Carcinoma: An Update].
Pezzicoli G; Ganini C; Re Sartò GV; Pirovano M; Cosmai L; Porta C
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007832
[TBL] [Abstract][Full Text] [Related]
26. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Gao X; McDermott DF
Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.
Larroquette M; Peyraud F; Domblides C; Lefort F; Bernhard JC; Ravaud A; Gross-Goupil M
Cancer Treat Rev; 2021 Jun; 97():102207. PubMed ID: 33906023
[TBL] [Abstract][Full Text] [Related]
28. Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery.
Stenman M; Benmakhlouf H; Wersäll P; Johnstone P; Hatiboglu MA; Mayer-da-Silva J; Harmenberg U; Lindskog M; Sinclair G
Acta Neurochir (Wien); 2021 Feb; 163(2):333-342. PubMed ID: 32902689
[TBL] [Abstract][Full Text] [Related]
29. Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors.
Jindal V; Gupta S
Mol Neurobiol; 2018 Aug; 55(8):7072-7078. PubMed ID: 29383686
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.
Mollica V; Santoni M; Di Nunno V; Cimadamore A; Cheng L; Lopez-Beltran A; Battelli N; Montironi R; Massari F
Curr Drug Targets; 2020; 21(14):1463-1475. PubMed ID: 32160846
[TBL] [Abstract][Full Text] [Related]
31. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
Yao C; Zhang T; Wu T; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(23):5013-5020. PubMed ID: 35819272
[TBL] [Abstract][Full Text] [Related]
32. Emerging resistance
Roy AM; George S
Cancer Drug Resist; 2023; 6(3):642-655. PubMed ID: 37842239
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.
Klausner G; Troussier I; Biau J; Jacob J; Schernberg A; Canova CH; Simon JM; Borius PY; Malouf G; Spano JP; Roupret M; Cornu P; Mazeron JJ; Valéry C; Feuvret L; Maingon P
Clin Genitourin Cancer; 2019 Jun; 17(3):191-200. PubMed ID: 30926219
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.
Bergerot P; Lamb P; Wang E; Pal SK
Mol Cancer Ther; 2019 Dec; 18(12):2185-2193. PubMed ID: 31792125
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.
Aparicio LMA; Fernandez IP; Cassinello J
Clin Transl Oncol; 2017 Oct; 19(10):1175-1182. PubMed ID: 28409322
[TBL] [Abstract][Full Text] [Related]
36. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
38. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
Parmar A; Ghosh S; Sahgal A; Lalani AA; Hansen AR; Reaume MN; Wood L; Basappa NS; Heng DYC; Graham J; Kollmannsberger C; Soulières D; Breau RH; Tanguay S; Kapoor A; Pouliot F; Bjarnason GA
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1763. PubMed ID: 36517084
[TBL] [Abstract][Full Text] [Related]
40. Continuation of immune checkpoint inhibitors for newly developed brain metastasis during immune checkpoint inhibitor treatment for oligoprogressive metastatic renal cell carcinoma.
Ishihara H; Fukuda H; Yoshida K; Hashimoto Y; Kondo T; Takagi T
Int J Urol; 2023 Feb; 30(2):240-242. PubMed ID: 36397731
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]